TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.47, sa.1, ss.40-46, 2017 (SCI-Expanded)
Background/aim: To evaluate the effect of intravitreal pro re nata (PRN) ranibizumab treatment from the start on the best-corrected visual acuity (BCVA) and the central retinal thickness (CRT) in macular edema (ME) due to branch retinal vein occlusion (BRVO).